2 Min Read
** Drugmaker's shares down 38.6 pct at near 7-year low of $16.33; biggest intraday pct fall in nearly 14 years
** Stock most actively traded on Nasdaq
** Multiple brokerages cut PT and rating after company slashes 2016 revenue and profit forecast to reflect operating challenges in its legacy generic business and pressures on a few of its core brand products
** Leerink cuts Endo's rating to "market perform" from "outperform", Mizuho to "underperform" from "neutral", Piper Jaffray to "neutral" from "overweight"
** Mizuho analysts say they view stock as "toxic," while RBC analysts say they think Endo needs to look at strategic alternatives at this point
** Lowering of guidance was not the surprise, but the magnitude was, Cowen & Co analysts write. "The question remains whether Endo can stabilize its core operations and begin to generate meaningful cash yield."
** Capital Research Global Investors is top shareholder; owned 23 mln shares as of March 31, about 10 pct of the company's shares outstanding
** Other drugmakers also fall on the news: Teva Pharmaceutical falls about 4 pct; Mylan NV dips about 2 pct; Horizon Pharma Plc falls about 6 pct
** Mallinckrodt Plc down 6.4 pct; Valeant Pharmaceuticals International Inc down 6.6 pct; Perrigo Co Plc falls about 2.2 pct, Allergan Plc down 2.8 pct
** 10 out of 20 brokerages rate stock "buy" or higher, remaining "hold"; median PT $45
** Up to Thursday's close, Endo stock had lost more than half of its value this year